Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weller

Showing results (611-620 of 831) with videos related to

Pageof 84
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2024
Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical ApplicationNicholas Mikolajewicz, Patricia P Yee, Debarati Bhanja, et al.
Nature|October 7, 2011
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptorChristiane A Opitz, Ulrike M Litzenburger, Felix Sahm, et al.
Neuro-Oncology|July 28, 2018
DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatmentHendrik Witt, Dorothee Gramatzki, Bettina Hentschel, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2018
Diagnostic value of <sup>18</sup>F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary siteFabian Wolpert, Michael Weller, Anna Sophie Berghoff, et al.
International Journal of Cancer|December 31, 2025
Conditional survival in glioblastoma: The evolution of prognostic factors over timeTimothy Mueller, Flavio Vasella, Julia Velz, et al.
The Lancet. Oncology|February 3, 2020
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative reportTerri S Armstrong, Linda Dirven, David Arons, et al.
The New England Journal of Medicine|March 11, 2005
MGMT gene silencing and benefit from temozolomide in glioblastomaMonika E Hegi, Annie-Claire Diserens, Thierry Gorlia, et al.
Oncotarget|November 12, 2016
Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cellsLindsay C Spender, G John Ferguson, Sijia Liu, et al.
Neuro-Oncology|October 10, 2024
Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1Martin J van den Bent, Enrico Franceschi, Mehdi Touat, et al.
Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
Pageof 84

Showing results (611-620 of 831) with videos related to

Sort By:
Pageof 84
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2024
Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical ApplicationNicholas Mikolajewicz, Patricia P Yee, Debarati Bhanja, et al.
Nature|October 7, 2011
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptorChristiane A Opitz, Ulrike M Litzenburger, Felix Sahm, et al.
Neuro-Oncology|July 28, 2018
DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatmentHendrik Witt, Dorothee Gramatzki, Bettina Hentschel, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2018
Diagnostic value of <sup>18</sup>F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary siteFabian Wolpert, Michael Weller, Anna Sophie Berghoff, et al.
International Journal of Cancer|December 31, 2025
Conditional survival in glioblastoma: The evolution of prognostic factors over timeTimothy Mueller, Flavio Vasella, Julia Velz, et al.
The Lancet. Oncology|February 3, 2020
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative reportTerri S Armstrong, Linda Dirven, David Arons, et al.
The New England Journal of Medicine|March 11, 2005
MGMT gene silencing and benefit from temozolomide in glioblastomaMonika E Hegi, Annie-Claire Diserens, Thierry Gorlia, et al.
Oncotarget|November 12, 2016
Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cellsLindsay C Spender, G John Ferguson, Sijia Liu, et al.
Neuro-Oncology|October 10, 2024
Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1Martin J van den Bent, Enrico Franceschi, Mehdi Touat, et al.
Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
Pageof 84